Ligand · F45
F45 · [6-(3,4-dihydroxyphenyl)pyridin-2-yl](4-fluoro-3-hydroxyphenyl)methanone
F45, [6-(3,4-dihydroxyphenyl)pyridin-2-yl](4-fluoro-3-hydroxyphenyl)methanone (C18 H12 F N O4, 325.3 g/mol), in the MolNFT structures on GenesisL1: bound in 7 records (5 PDB entries). Every binding site with its residues within 4.5 Å, the…
- Component
- F45
- Formula
- C18 H12 F N O4
- Class
- ligand
- Structures
- 7
- PDB entries
- 5
Binding sites
F45 in 7 structures; the first of them:
- 5ICM · 17beta-hydroxysteroid dehydrogenase type 14 in complex with a non-steroidal inhibitor · F45 A303 · binds HIS93, PRO96, SER141, VAL143, GLN148, ALA149, GLN150, ALA151 and 7 more
- 6FFB · 17beta-hydroxysteroid dehydrogenase 14 variant S205 - mutant Q148A - in complex with a… · F45 A304 · binds HIS93, PRO96, SER141, LEU142, VAL143, ALA148, ALA149, GLN150 and 9 more
- 6ZR6 · 17beta-hydroxysteroid dehydrogenase type 14 variant S205 in complex with non-steroidal… · F45 A304 · binds HIS93, PRO96, SER141, LEU142, VAL143, GLN148, ALA149, GLN150 and 8 more
- 6FFB · 17BETA-hydroxysteroid dehydrogenase 14 variant S205 - mutant Q148A - in complex with a… · F45 A304 · binds HIS93, PRO96, SER141, VAL143, ALA149, GLN150, ALA151, TYR154 and 7 more
- 6G4L · 17BETA-hydroxysteroid dehydrogenase type 14 mutant Y253A in complex with a non-steroidal… · F45 A304 · binds HIS93, PRO96, SER141, VAL143, GLN148, ALA149, GLN150, ALA151 and 7 more
- 6GBT · 17BETA-hydroxysteroid dehydrogenase type 14 mutant Y253A in complex with a non-steroidal… · F45 A302 · binds HIS93, PRO96, SER141, VAL143, GLN148, ALA149, GLN150, ALA151 and 5 more
- 6ZR6 · 17BETA-hydroxysteroid dehydrogenase type 14 variant S205 in complex with non-steroidal… · F45 A304 · binds HIS93, PRO96, SER141, VAL143, GLN148, ALA149, GLN150, ALA151 and 7 more
Residues it binds most
ALA 7, LEU 7, PRO 7, GLN 7, ASN 7, HIS 7, SER 7, TRP 7, TYR 7, VAL 7 (residue and the binding sites it lines).
Found with
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.